Managing residual risk in patients receiving statin therapy
Author: Ian R Hamilton-Craig
Published online: 3 January 2011
In reply: In the interests of scientific exactitude, I am indebted to Marilyn Mann for corrections regarding the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. However, as the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial did not include the control group ezetimibe versus placebo, the effects of ezetimibe on carotid intima media thickness remain somewhat speculative.1
Competing interests
References
- Stein E. After ENHANCE: is more LDL cholesterol lowering even better? Clin Chem 2008; 54: 940-942. 0_JJJHADGB
Fatty Liver Disease in Australia: A Narrative Review on the Epidemiology, Natural History, Prognostication and Management in People With Metabolic Dysfunction
Karl Vaz, Daniel Clayton-Chubb, William W. Kemp, Stuart K. Roberts, Ammar Majeed
Sex Differences in Management and Outcomes of People With ST-Elevation Myocardial Infarction, New South Wales, 2011–2020: A Retrospective Cohort Study
Adam C. Livori, Jedidiah I. Morton, Dianna J. Magliano, Jonathan E. Shaw
Rethinking Rheumatic Fever Diagnosis: Progress, Pitfalls and the Path Towards a Definitive Test
Anna P. Ralph, Rachel Webb, Tom Parks, Nicole J. Moreland, Asha C. Bowen, Benjamin Jones, Emma Ndagire, Andrea Z. Beaton
Sex Differences in Management and Outcomes of People With ST-Elevation Myocardial Infarction, New South Wales, 2011–2020: A Retrospective Cohort Study
Samia Kazi, Simone Marschner, Clara K. Chow
Distribution of Cardiovascular Disease Risk Based on the Updated 2023 Guideline-Recommended Australian Cardiovascular Disease Risk Algorithm and Comparison With the 2012 Algorithm: An Observational Study
Nina Lazarevic, Meghana Bhat, Grace Joshy, Danielle C. Butler, Mark Woodward, Anushka Patel, Rod T. Jackson, Garry Jennings, Rosemary Wyber, Ellie Paige, Emily Banks
They Brought the Hospital to Me
Hugh N. Burrill